Fabry Disease Market Outlook: 6 Upcoming Therapies Set to Influence the Future Market Landscape | DelveInsight

DelveInsight estimates the Fabry disease market across the U.S., EU4, UK and Japan was worth approximately $1.7 billion in 2025 and will grow at a significant CAGR through 2036, supported by next-generation enzyme therapies, substrate-reduction drugs and gene therapies. Sangamo is advancing a rolling BLA for ST-920, potentially completing the filing in summer 2026, while Idorsia's FDA-approved Phase III registration program for lucerastat and uniQure's early-stage AMT-191 data add to the late-stage pipeline. The report highlights durable gene-therapy approaches as a potential means to reduce infusion burden and improve disease control, though most candidates remain investigational.

Analysis

The key investable issue is not category growth but displacement economics. A durable therapy that permits withdrawal from chronic enzyme replacement could remove a high-margin, recurring orphan-drug revenue stream from SNY, while limiting the value of incremental ERT share gains for PLX. In the first 12-24 months after any launch, however, switching should be constrained by conservative nephrology/genetics practice, payer demand for durability data, eligibility exclusions, and the need to preserve ERT in patients with advanced organ damage; near-term revenue erosion for incumbents is therefore likely lower than the headline disruption risk implies.

SGMOQ's valuation sensitivity is unusually binary: BLA filing completeness, FDA acceptance, label language around baseline ERT withdrawal, and a commercial partner capable of funding launch will matter more than additional biomarker presentations. A partnership would reduce financing overhang and validate commercial economics, but could also cap upside if structured as an asset sale or heavily back-end-loaded royalty. The company-sponsored and market-research nature of the source means no new independently verified efficacy, manufacturing, durability, or regulatory information is established here.

QURE has favorable strategic read-through from investor attention to liver-directed Fabry gene transfer, but its program remains sufficiently early that it should not be valued as a direct approval competitor. The contrarian view is that competitive crowding may weaken—not strengthen—the economics of all Fabry gene-therapy assets: a small addressable population, AAV antibody exclusions, uncertain redosing, and payer resistance to large upfront payments can force lower net prices and require longer durability evidence. Over 6-18 months, this is more likely to pressure gene-therapy revenue multiples than expand them unless a registrational asset demonstrates sustained renal/cardiac benefit and credible ERT independence.

Key Decisions for Investors

• Maintain SGMOQ as a catalyst watch rather than add on this release. Enter only after independently confirmed BLA completion/acceptance and financing runway disclosure; size as a 1-3 month event position, with upside tied to a partnership or priority review and thesis failure on filing delay, CRL, or dilutive capital raise.
• For 6-18 month exposure, consider a modest long SGMOQ / short SNY pair only after regulatory acceptance: it isolates Fabry disruption from broad biotech beta. Exit if the label restricts use to a narrow subgroup, durability does not support ERT discontinuation, or SNY demonstrates stable Fabry franchise guidance despite switching.
• Do not extrapolate the Fabry narrative into QURE. Monitor AMT-191 updates for sustained enzyme expression, lyso-Gb3 reduction, renal/cardiac endpoints, immunosuppression burden, and patient eligibility; absent those data, competitive validation is not sufficient to support a new long.
• Watch PLX quarterly ELFABRIO patient starts and net-product-revenue trajectory over the next 2-4 quarters. A deceleration would be an earlier, tradeable indicator of channel caution and potential modality displacement, while continued growth would falsify an imminent ERT-share-loss thesis.